

Hormone Products for Postmenopausal Use in the United States and Canada

Compiled by The North American Menopause Society
November 9, 2007

**Table 1. Oral ET Products for Postmenopausal Use
in the United States and Canada**

Composition	Product Name	Available Dosages (mg)
conjugated estrogens (formerly conjugated equine estrogens)	Premarin	0.3, 0.45*, 0.625, 0.9, 1.25
synthetic conjugated estrogens, A	Cenestin*	0.3, 0.45, 0.625, 0.9, 1.25
	Congest**	0.3, 0.625, 0.9, 1.25, 2.5
	C.E.S**	0.3, 0.625, 0.9, 1.25
	PMS-Conjugated**	0.3, 0.625, 0.9, 1.25
synthetic conjugated estrogens, B	Enjuvia*	0.3, 0.45, 0.625, 0.9, 1.25
esterified estrogens	Menest*	0.3, 0.625, 1.25, 2.5
	Neo-Estrone**	0.3, 0.625, 1.25
17 β -estradiol	Estrace	0.5, 1.0, 2.0
	various generics	0.5, 1.0, 2.0
estradiol acetate	Femtrace*	0.45, 0.9, 1.8
estropipate (formerly piperazine estrone sulfate)	Ortho-Est*	0.625 (0.75 estropipate, calculated as sodium estrone sulfate 0.625), 1.25 (1.5), 2.5 (3.0)
	Ogen** various generics	0.625 (0.75), 1.25 (1.5), 2.5 (3.0) 0.625 (0.75), 1.25 (3.0)

* Available in the United States but not Canada.

** Available in Canada but not the United States.

Products not marked are available in the United States and Canada.

Table 2. Transdermal and Topical ET Products for Postmenopausal Use in the United States and Canada

Composition	Product Name	Delivery Rate (mg/day)	Dosing
17 β -estradiol matrix patch	Alora*	0.025, 0.05, 0.075, 0.1	twice weekly
	Climara	0.025, 0.0375*, 0.05, 0.075, 0.1	once weekly
	Esclim*	0.025, 0.0375, 0.05, 0.075, 0.1	twice weekly
	Estradot**	0.025, 0.0375, 0.05, 0.075, 0.1	twice weekly
	Menostar*	0.014	once weekly
	Oesclim**	0.05, 0.1	twice weekly
	Vivelle	0.05, 0.1*	twice weekly
	Vivelle-Dot*	0.025, 0.0375, 0.05, 0.075, 0.1	twice weekly
	various generics	0.1, 0.05	once or twice weekly
17 β -estradiol reservoir patch	Estraderm	0.05, 0.1	twice weekly (patch cannot be cut)
17 β -estradiol transdermal gel	EstroGel 0.06%* Estrogel 0.06%**	0.035	daily application; 1 metered pump delivers 1.25 g of gel containing 0.75 mg 17 β -estradiol
	Elestrin 0.06%*	0.0125	daily application; 1 metered pump delivers 0.87 g of gel containing 0.52 mg 17 β -estradiol
	Divigel 0.1%*	0.003, 0.009, 0.027	daily application; 3 strengths of packets provide 0.25, 0.5, or 1.0 g of gel
17 β -estradiol topical emulsion	Estrasorb*	0.05 (2 packets)	daily application of 2 packets; 1 packet = 1.74 g of emulsion
17 β -estradiol transdermal spray	Evamist*	0.021 mg per 90 mcL spray (metered-dose pump)	initial: 1 spray/d of 1.7% solution, increasing to 2-3 sprays/d if needed

* Available in the United States but not Canada.

** Available in Canada but not the United States.

Products not marked are available in the United States and Canada.

Table 3. Vaginal ET Products for Postmenopausal Use in the United States and Canada

Composition	Product Name	Dosing
<i>Vaginal Creams</i>		
17 β -estradiol	Estrace Vaginal Cream*	initial: 2-4 g/d for 1-2 wk maintenance: 1 g/d (0.1 mg active ingredient/g)
conjugated estrogens (formerly conjugated equine estrogens)	Premarin Vaginal Cream	0.5-2 g/d (0.625 mg active ingredient/g)
esterified estrogens	Neo-Estrone Vaginal Cream**	2-4 g/d (1 mg active ingredient/g)
<hr/>		
<i>Vaginal Rings</i>		
17 β -estradiol	Estring	device containing 2 mg releases 7.5 μ g/d for 90 days
estradiol acetate	Femring*	device containing 12.4 mg or 24.8 mg estradiol acetate releases 0.05 mg/d or 0.10 mg/d estradiol for 90 days (<u>systemic levels</u>)
<hr/>		
<i>Vaginal Tablet</i>		
estradiol hemihydrate	Vagifem	initial: 1 tablet/d for 2 wk maintenance: 1 tablet twice/wk (tablet containing 25.8 μ g of estradiol hemihydrate equivalent to 25 μ g of estradiol)

* Available in the United States but not Canada.

** Available in Canada but not the United States.

Products not marked are available in the United States and Canada.

**Table 4. Progestogens Used for EPT
in the United States and Canada**

Composition	Product Name	Available Dosages
<i>Oral Tablet: Progestin</i>		
medroxyprogesterone acetate	Provera, various generics	2.5, 5, 10 mg
norethindrone (formerly norethisterone)	Micronor, Nor-QD,* various generics	0.35 mg
norethindrone acetate	Aygestin,* various generics	5 mg
norgestrel	Ovrette*	0.075 mg
megestrol acetate	Megace, various generics	20*, 40 mg
<hr/>		
<i>Oral Capsule: Progesterone</i>		
progesterone (in peanut oil)	Prometrium	100, 200* mg
<hr/>		
<i>Intrauterine System: Progestin</i>		
levonorgestrel	Mirena	20 µg/day approx release rate (52 mg IUS has 5-yr use)
<hr/>		
<i>Vaginal Gel: Progesterone</i>		
progesterone	Prochieve 4%* Crinone 4%**	45 mg/applicator

* Available in the United States but not Canada.

** Available in Canada but not the United States.

Products not marked are available in the United States and Canada.

Table 5. Combination EPT Products for Postmenopausal Use in the United States and Canada

Composition	Product Name	Available Dosages (mg/day)
<i>Oral Continuous-Cyclic Regimen</i>		
conjugated estrogens (E) + medroxyprogesterone acetate (P) (E alone for days 1-14, followed by E + P on days 15-28)	Premphase*	0.625 mg E + 5.0 mg P (2 tablets: E and E + P)
<i>Oral Continuous-Combined Regimen</i>		
conjugated estrogens (E) + medroxyprogesterone acetate (P)	Prempro*	0.625 mg E + 2.5 or 5.0 mg P (1 tablet); 0.3 or 0.45 mg E + 1.5 mg P (1 tablet)
	Premplus**	0.625 mg E + 2.5 or 5.0 mg P (2 tablets: E and P)
ethinyl estradiol (E) + norethindrone acetate (P)	femhrt*	2.5 µg E + 0.5 mg P (1 tablet); 5 µg E + 1mg P (1 tablet)
	femHRT**	5 µg E + 1 mg P (1 tablet)
17β-estradiol (E) + norethindrone acetate (P)	Activella*	0.5 mg E + 0.1 mg P (1 tablet); 1 mg E + 0.5 mg P (1 tablet)
17β-estradiol (E) + drospirenone (P)	Angeliq*	1 mg E + 0.5 mg P (1 tablet)
<i>Oral Intermittent-Combined Regimen</i>		
17β-estradiol (E) + norgestimate (P) (E alone for 3 days, followed by E+P for 3 days, repeated continuously)	Prefest*	1 mg E + 0.09 mg P (2 tablets: E and E + P)
<i>Transdermal Continuous-Combined Regimen</i>		
17β-estradiol (E) + norethindrone acetate (P)	CombiPatch,* Estalis**	0.05 mg E + 0.14 mg P (9 cm ² patch, twice/wk); 0.05 mg E + 0.25 mg P (16 cm ² patch, twice/wk)
17β-estradiol (E) + levonorgestrel (P)	Climara Pro*	0.045 mg E + 0.015 mg P (22 cm ² patch, once/wk)
<i>Transdermal Continuous-Sequential Regimen</i>		
17β-estradiol (E) + norethindrone acetate (P) (E alone for 2 wks, followed by E+P for 2 wks, repeated continuously)	Estalis Sequi**	0.05 mg E twice/wk (Vivelle 50 patch) for 2 wks, then 9 or 16 cm ² Estalis patch twice/wk for 2 wks
	Estracomb**	0.05 mg E twice/wk for 2 wks, then 0.05 mg E + 0.25 mg P for 2 wks

* Available in the United States but not Canada.

** Available in Canada but not the United States.

Table 6. Oral Estrogen-Testosterone Products for Postmenopausal Use in the United States and Canada

Composition	Product Name	Available Dosages
esterified estrogens (E) + methyltestosterone (T)	Estratest,* various pseudo-generics*†	1.25 mg E + 2.5 mg T
	Estratest HS,* various pseudo-generics*†	0.625 mg E + 1.25 mg T

* Available in the United States but not Canada.

† Since Estratest and Estratest HS are not FDA-approved but permitted on the US market by the FDA while additional studies are being conducted, there can be no generic equivalent as defined in the regulations.